Nivolumab with ipilimumab adjuvant therapy for renal cell carcinoma


featured image

Nivolumab in combination with ipilimumab is in clinical development as adjuvant therapy for adult patients with localised renal cell carcinoma (RCC) who underwent partial or entire removal of a kidney.

Therapeutic Areas: Renal Cancer
Year: 2022

Nivolumab in combination with ipilimumab is in clinical development as adjuvant therapy for adult patients with localised renal cell carcinoma (RCC) who underwent partial or entire removal of a kidney. RCC (the most common type of kidney cancer in adults) is a disease that affects the lining of tiny tubes within the kidney which filter waste from the blood, making urine. Localised RCC means the cancer is either completely inside the kidney or has grown into surrounding tissues but has not spread to another part of the body. The main treatment for RCC is surgery to remove part or the whole kidney. After surgery, the disease may relapse and spread to other parts of the body. The aim of adjuvant treatment for localised RCC is to reduce the number of people whose disease relapses after surgery, and this remains an unmet need.